alpha-aminopyridine has been researched along with methotrexate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Burgos-Vargas, R; Dikranian, AH; Grossbard, E; Kavanaugh, A; Medrano-Ramirez, G; Morales-Torres, JL; Murphy, FT; Musser, TK; Straniero, N; Vicente-Gonzales, AV; Weinblatt, ME | 1 |
| Genovese, MC; Grossbard, EB; Kavanaugh, A; Magilavy, DB; Musser, TK; Weinblatt, ME | 1 |
| Andreu, JL; Otón, T; Silva-Fernández, L | 1 |
| Baluom, M; Grossbard, EB; Lau, DT; Samara, E | 1 |
| Genovese, MC; Ho, M; Hollis, S; Kavanaugh, A; Leon, G; Millson, DS; Rosiak-Jedrychowicz, K; van der Heijde, D; Wang, M; Weinblatt, ME | 1 |
| Benhamou, C; Duffield, EL; Fudman, E; Genovese, MC; Kavanaugh, A; Keystone, EC; Lampl, K; O'Brien, C; Poiley, J; Spindler, AJ; van der Heijde, DM; Weinblatt, ME | 1 |
| Byeon, HK; Cho, BC; Choi, JW; Hong, MH; Jung, I; Kang, HN; Kim, DH; Kim, HR; Kim, J; Kim, JH; Koh, YW; Lee, H; Lim, SM; Paik, S; Park, AY; Park, YM; Pyo, KH; Shin, EJ; Yoon, SO; Yun, MR | 1 |
| Iwata, S; Millson, D; Nakayamada, S; Tanaka, Y | 1 |
| Cai, J; Cai, Q; Fang, Y; Huang, H; Li, Z; Liu, P; Ma, S; Su, N; Tian, X; Wang, J; Xia, Y; Zhang, Y | 1 |
6 trial(s) available for alpha-aminopyridine and methotrexate
| Article | Year |
|---|---|
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Arthritis, Rheumatoid; Double-Blind Method; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase | 2008 |
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Statistics, Nonparametric; Syk Kinase; Treatment Outcome | 2010 |
Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase | 2011 |
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome; Young Adult | 2014 |
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Topics: Adult; Aminopyridines; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Morpholines; Oxazines; Patient Safety; Prognosis; Pyridines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
Topics: Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Asia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Pyridines; Pyrimidines | 2021 |
3 other study(ies) available for alpha-aminopyridine and methotrexate
| Article | Year |
|---|---|
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Intracellular Signaling Peptides and Proteins; Methotrexate; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase | 2011 |
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Topics: Afatinib; Aminopyridines; Animals; Biopsy; Carcinoma, Squamous Cell; Gene Amplification; Gene Regulatory Networks; Genetic Variation; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Methotrexate; Mice; Morpholines; Papillomavirus Infections; Patient-Specific Modeling; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |